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When studying transcription factors, it is necessary to investigate posttranslational modiﬁcations. Histone acetyltransferases
(HATs) are typical of the modiﬁcation enzymes involved in chromatin regulation. HATs acetylate the transcription factors
(nonhistone proteins) as well as histones. Interferon regulatory factors (IRFs) are transcription factors that bind to the interferon
regulatory element(IRF-E) andareinvolvedinregulating cell growth,diﬀerentiation,andtheimmuneandhematopoieticsystems.
During the process of binding to a speciﬁc DNA element, IRFs also bind to coactivators such as HATs and become modiﬁed. This
review looks at how IRFs associate with HATs, p300, and PCAF, and thereby contribute to transcriptional activation.
1.Introduction
Cellular proteins are posttranslationally modiﬁed by var-
ious mechanisms, including acetylation, deacetylation,
phosphorylation, and methylation. The reversible acetyla-
tion of histone and nonhistone proteins plays a key role
in maintaining cellular homeostasis [1, 2]. The acetylation
of histones is a prerequisite for transcriptional activation.
Transcription factorsare recruitedtothechromatin byacety-
lated histones, thereby leading to transcriptional activation.
In addition to transcription, the status of histone acetylation
may inﬂuence cell growth and diﬀerentiation [3]. Similarly,
the acetylation of several transcription factors may regulate
their function, by multiple mechanisms, including the mod-
iﬁcation of DNA binding ability, secondary protein-protein
interactions, protein half-life, and protein localization.These
events, in turn, can inﬂuence DNA repair, cell cycle pro-
gression, apoptosis, and various signaling pathways. Many
diﬀerent transcription factors that are regulated through
acetylation have been reported over the past decade.
Interferon regulatory factors (IRFs) were characterized
as interferon- (IFN-)responsive transcription factors and
were investigated through immune response to pathogens,
immunomodulation, and hematopoieticdevelopment[4,5].
As we will describe below, IRFs are transcription factors that
have been shown to be acetylated by histone acetyltrans-
ferases (HATs) [6, 7]. Such IRFs modiﬁcations are associated
with cell growth and diﬀerentiation as well as the IFN
response. IRFs also associate with several HATs to regulate
the transcription of speciﬁc genes. Here, we introduce a
role for acetylated IRFs or IRF-HAT complexes in speciﬁc
signaling pathways and cell functions.
2.HistoneAcetyltransferases(HATs)
There is a growing body of evidence supporting the notion
that acetylation, like phosphorylation, is an important
regulatory protein modiﬁcation. HATs are increasingly being
recognized as modiﬁers of both histones and nonhistone
proteins [2]. Many HATs have been identiﬁed such as
the GNAT superfamily (PCAF, GCN5), p300/CBP, MYST
family proteins including MOZ, and nuclear receptor coac-
tivators. HATs function enzymatically by transferring an
acetyl group from acetyl-coenzyme A (acetyl-CoA) to an
ε-amino group of certain lysine side chains within a histone’s
basic N-terminal tail region. Lysine acetylation neutralizes2 Journal of Biomedicine and Biotechnology
part of a histone tail region’s positive charge, resulting in
weakened histone-DNA or nucleosome-nucleosome inter-
actions [8]. Acetylated chromatin prefers to associate with
transcription factors. HATs also acetylate lysine residues
within transcription-related proteins as well as histones.
HAT proteins form multiple complexes and are recruited to
chromatin toacetylate histones ortotranscription factors. In
terms of IRF regulation by acetylation, PCAF and CBP/p300
play especially important roles.
3.The IRFFamilyof TranscriptionFactors
Interferon regulatory factors (IRFs) are transcription factors
which participate in the early host responses to pathogens,
immunomodulation, and hematopoiesis [5, 9]. Nine mam-
malian members of the IRF family (IRF-1, -2, -3 , -4, -5,
-6, -7, -8, and -9) have been identiﬁed. All IRFs carry a
conserved DNA-binding domain (DBD) consisting of ∼110
amino acids in the N-terminal region. The DBD contains
a unique helix-turn-helix motif, and it is responsible for
bindingtotheIFN-regulatoryfactorelement(IRF-E)present
in the IFN-β promoter [10, 11]. Notably, the consensus
sequence of the promoter, G(A)AAAG/CT/CGAAAG/CT/C,
is almost indistinguishable from the interferon-stimulated
response element (ISRE) activated by IFN signaling. IRF
function directly correlates with its sequence-speciﬁc bind-
ing to the promoters of its regulatory genes. Various post-
translational modiﬁcations of IRF proteins aﬀect a host’s
response to pathogens as well as hematopoietic diﬀerentia-
tion, immunomodulation, and oncogenesis.
Among the members of the IRF family, IRF-1 and IRF-
2 were originally identiﬁed through transcriptional studies
of the human IFN-β gene [10, 11]. Both IRF-1 and IRF-
2 expressed in most cell types and are type I IFN and
type II IFN inducible protein. Although IRF-1 and IRF-
2 have a high ability of binding to IRF-E, they have
opposing activities. Whereas IRF-1 activates transcription
from promoters carrying the ISRE, IRF-2 represses the
transcription of these promoters in IFN system. Both IRF-
1 and IRF-2 mRNAs are expressed at low constitutive levels
in the cell, but the IRF-2 protein is more stable and thus
accumulates at higher levels (the half-lives of IRF-1 and
IRF-2 are 30min versus 8h, resp.) [12]. In addition, IRF-1




We previously demonstrated that IRF-1 and IRF-2 both
interact with the histone acetyltransferase PCAF in vitro and
that this interaction plays an important role in controlling
transcription from relevant promoters [6, 13, 14]. IRF-
1s t i m u l a t e sI F N - β promoter with PCAF whereas PCAF
enhances IRF-2-dependent H4 promoter activation. Thus,
PCAF binding to the IRFs enhances the IRFs-activated
promoter. We also demonstrated that the IRF-2 DNA-
binding domain interacts with the PCAF bromodomain
[13]. Bromodomain is identiﬁed by sequence alignment
as a ∼60-amino acid motif conserved among Drosophila
Brahma and female-sterile homeotic (fsh) genes and four
other potential transcription regulators [15]. Among HATs,
PCAF, GCN5, p300, and CBP are bromodomain-containing
proteins. The bromodomain of PCAF has a speciﬁc aﬃnity
for acetyllysine-containing motifs [16].PCAFbromodomain
may associate with the acetylated lysine residue (Lys-75
and Lys-78) within the IRF-2 DNA-binding domain [14].
Although both IRF-1 and IRF-2 are acetylated in vitro [6],
the level of acetylation is signiﬁcantly higher for IRF-2 than
for IRF-1. IRF-2 is described as a transcriptional repressor
of IFN-responsive genes, and it appears to function by
competing with the transcriptional activator IRF-1. We have
demonstrated that acetylated IRF-2 inhibits p300-mediated
acetylation of core histones [6]. Phorbol esters such as 12-
O-tetradecanoylphorbol-13-acetate (TPA) activate protein
kinase C and stimulate the diﬀerentiation of U937 cells
toward macrophage-like cells. Under these conditions, TPA
treatment induces the acetylation of nuclear core histones.
IRF-2 associates with p300 and PCAF and becomes acety-
lated in TPA-treated U937 cells. Acetylated IRF-2 reduces
the acetylation of histones H2A and H2B in TPA-stimulated
U937 cells. One interpretation of this observed inhibition is
that IRF-2, by acting as a substrate for histone acetylases,
competitively inhibits histone acetylation (Figure 1(a)). IRF-
2 inhibition of histone acetylation is relevant to IRF-2’s tran-
scriptional repression of IFN-responsive genes. Another IRF
member, v-IRF (derived from Kaposi’s sarcoma-associated
herpes virus) interacts with p300 to similarly inhibit core
histone acetylation, resulting in the repressed transcription
of interferon-responsive genes [17].
In contrast, IRF-2 can act as a positive regulator for
ISRE-like sequences such as the H4 promoter [18, 19]. IRF-
2 is acetylated during the active growth of NIH3T3 cells
(i.e., nonconﬂuent conditions), and acetylated IRF-2 binds
to the H4 promoter, thus participating in gene regulation
for controlling cell growth. Acetylated IRF-2 may also
interact with other proteins, resulting in more eﬃcient gene
transcription. Nucleolin, a nuclear protein, preferentially
associates with acetylated IRF-2, over nonacetylated IRF-2,
resulting in a more eﬃcienttranscriptionoftheH4gene[20]
(Figure 1(b)).
IRF-2 binds to PCAF (and p300) and is then subject to
acetylation at the lysine residue. Two lysine residues in the
D B D ,L y s - 7 5 ,a n dL y s - 7 8a r ef o u n dt ob et h em a j o ra c e t y -
lation sites of IRF-2. Lys-75 is the major site of acetylation
by p300 and PCAF whereas Lys-78 is acetylated to a lesser
degree. Lys-78 in IRF-2 is a residue conserved throughout
members of the IRF family. Amino acid mutation of Lys-
78 in IRF-2 led to the abrogation of DNA binding activity
independently of acetylation [14]. According to the crystal
structure of the IRF-1 DNA-binding domain bound to a
DNA target sequence, lysine 78 (corresponding to lysine
92 in IRF-7) stabilizes the protein-DNA complex through
hydrogen bonding. Neutralization of the positive charge of
this lysine residue eﬀectively tightens the bonds between the
transcriptional complex and the promoter [21]. Acetylation
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Figure 1: Two diﬀerent functions of interferon regulatory factor-2 (IRF-2) through its acetylation by HAT. (a) During TPA-induced
cell diﬀerentiation, IRF-2 binds histone acetylases, p300, and PCAF and inhibits core histone acetylation, resulting in the inhibition of
IFN-inducible genes. (b) IRF-2 binds to PCAF and is acetylated. Acetylated IRF-2 is recruited to nuclear protein, nucleolin. The IRF-
2/PCAF/nucleolin complex contributes to cell growth through the activation of ISRE-like site in the H4 gene promoter.
ability. In the case of IRF-2, acetylation recruits cofactor
(nucleolin) to the transcription factor-DNA complex [20].
As mentioned above, IRF-1 is a positive regulator for
the IFN-producing system, and stimulates IFN-β promoter
with PCAF in the in vitro luciferase assay in cultured cells
[13]. Dornan et al. reported that the interaction with IRF-
1 and p300 is important for synergizing activity of the
p53-induced p21 gene activation, independent of IRF-1’s
DNA binding activity [22]. In their investigation, deletion
of the p300-binding sites in IRF-1 eliminates the ability
of IRF-1 to stimulate p53 acetylation and associated p53
activity. The nonacetylatable p53 mutant (p53-6KR) cannot
be stimulated by IRF-1. They concluded that IRF-1 binding
top300stabilizesp300bindingtothetransactivation domain
of p53, including p53 acetylation. Another report indicates
that IRF-1 is acetylated and associates with HATs to form
a complex that assembles on the HIV-1LTR promoter, and
CBPisrecruited by IRF-1 to HIV-1LTR promoterevenin the
absence of Tat [23].
5. IRF-3and IRF-7
IRF-3 and IRF-7 are involved in IFN gene expression during
viral infections. IRF-3 speciﬁcally targets IFN-α and IFN-
β whereas IRF-7 is required for the induction of additional
members of the IFN-α multigene family. In its inactive form,
IRF-3 is restricted to the cytoplasm in unstimulated cells.
Viral infection or treatment with dsRNA triggers a signal,
which results in the speciﬁc phosphorylation of speciﬁc ser-
ine residues in IRF-3. The phosphorylated IRF-3 assembles
intoahomodimerand thenformsacomplexwith thecoacti-
vatorsCBP/p300inthenucleus[24,25].Speciﬁcphosphory-
lation sites such as Ser-386, were identiﬁed for IRF-3 dimer-
ization (activation) [26, 27]. The histone acetyltransferase
p300is requiredfor theDNAbinding bythe IRF-3holocom-
p l e x ,w h i c hl e a d st oI F N - β transcriptional activation.
IRF-7 is activated by virus-induced phosphorylation on
serine residues within the C-terminal regulatory domain,
resulting in induction of the IFN-α gene [28]. Caillaud
et al. found that IRF-7 is acetylated by PCAF and GCN5
at a single lysine residue (Lys-92) which is located in the
DBD and is conserved throughout the entire IRF family [7].
They reported that acetylated IRF-7 displays an impaired
DNA binding capability and that PCAF repression leads to
decreased IRF-7 activity. One may conclude that acetylation
of lys-92, negatively modulates IRF-7 DNA binding. As a
general rule, if the acetylation occurs within a DNA-binding
domain, it will repress the DNA binding, and if it occurs
adjacent to a DNA-binding domain, then it will activate
DNA binding. Not surprisingly, the precise eﬀect of lysine
acetylation depends on the location of the target residue.
DNAbinding ability is regulated by acetylation of target sites
(amino acids) in the case of IRF-7 [7].
Yang et al. reported that IRF-3 and IRF-7 synergistically
activate the virus-induced IFN-β promoter in the presence
of the p300/CBP coactivator [29]. The IFN-β promoter
contains a binding site for the ATF-2/c-Jun, IRFs, and Rel
families, and ATF-2, c-Jun, IRF-3, IRF-7, and NF-kB are
associated with the IFN-β promoter in virus-infected cells
in vivo [30]. The eﬀects of ATF-2/c-Jun, IRF-1, IRF-3/IRF-7,
and NF-kB, on the transcription of -100IFNbCAT reporter
in the presence or absence of mammalian p300/CBP have
been studied. IRF-1 was able to activate -100IFNbCAT on its
own, however, IRF-1 did not stimulate transcription when
combined with other factors, more than the sum of their
individual eﬀects, regardless of whether or not p300/CBP
was present. In contrast, IRF-3/IRF-7 with ATF-2/c-Jun,
or NF-kB showed a synergistic eﬀect in the presence of
p300/CBP although only IRF-3/IRF-7 had no eﬀect on the
promoter [29]. Moreover, no synergy was observed in the
absence of either p300/CBP or IRF-3/IRF-7. p300/CBP play
an important role for the functional activation of both IRF-3
and IRF-7 upon virus infection.
6.HATsinInterferonSignaling
The transcription of the IFN-β gene in response to a
viral infection requires the assembly of an enhanceosome,
consisting of the transcriptional activators NF-kB, IRF-1,
ATF2/c-Jun and HMGI(Y) [31, 32]. The enhanceosome acti-
vates transcription by recruiting the CBP/p300 coactivator
that is associated with the Pol II holoenzyme complex.
CBP and PCAF can acetylate HMGI(Y) at distinct lysine
residues, causing opposing eﬀects on IFN-β gene expression.
Acetylation of HMGI(Y) by CBP causes enhanceosome dis-
ruption leading to the termination of IFN-β gene activation.4 Journal of Biomedicine and Biotechnology
Furthermore, CBP-enhanceosome interactions are responsi-
bleforthefastrecruitmentofthePolIIholoenzyme,ensuring
rapidactivationofIFN-βgeneexpression in response toviral
infection [33]. In addition, viral infection induces recruit-
ment of IRF-2 to some of endogenous IFN-β enhancers
as part of the enhanceosome assembly process, and IRF-
2 incorporation into enhanceosomes restricts the num-
ber of IFN-β promoters directing transcription [34]. The
repression mechanism of IRF-2 against the enhanceosome
has also been investigated. IRF-2 repressed transcription
neither by competitive DNA binding nor by directly or
indirectly inhibiting assembly of the basal transcriptional
machinery directly or indirectly. Senger et al. demonstrated
that incorporation of IRF-2 into IFN-β enhanceosomes
blocks recruitment of CBP and the associated RNA Pol II
and strongly inhibits activation of transcription [34]. This
inhibition is not mediated by another protein recruited by
IRF-2, but rather by the IRF-2 repression domain itself,
while the IRF-2 repression domain interacts with neither the
activators nor CBP, but blocks recruitment of CBP.
In contrast, the requirement for deacetylase activity in
IFN-α-inducible gene regulation has been reported [35].
IFN-α stimulation induces local histone H4 deacetylation,
and the deacetylase HDAC1 associates with both STAT1
and STAT2. The deacetylase activity of HDAC1 acts as
a positive coactivator for ISGF3-dependent transcriptional
responses and enhances IFN-α-induced transcription. The
requirement for deacetylase activity is shared by IFN-γ
signaling through STAT1. The role of HDAC1 in IFN




Histone deacetylases (HDACs) are also associated with IRF-
dependent transcription. For instance, the HPV E7 protein
binds to HDAC and interferes with the transactivation
function of IRF-1 by recruiting HDAC to the IFN-β
promoter [36]. HPV E7 interferes with the IFN-signaling
function of IRF-1 by recruiting HDAC to the speciﬁc
promoter. IRF-5, another IRF family member, is known to
regulate proinﬂammatory cytokine expression [37]. Feng et
al. showed that both HDACs and HATs associate with IRF-
5 and alter in its transcriptional activity [38]. They also
demonstrated byusing trichostatin A(TSA)thatISRE,IFNA,
and IL-6 promoters, but not TNF-α,r e q u i r eH D A Ca c t i v i t y
for transactivation. The HATs CBP and p300 bind and
acetylate IRF-5. HDAC and HATs are recruited to IRF-5 in a
distinct region and play an important role fortranscriptional
induction of proinﬂammatory cytokines mediated by IRF-5.
8.AnotherIRF Family,c-Myb, and Other
TranscriptionFactors
The IRF family shares homology with the myb oncopro-
teins. The c-myb proto-oncogene product (c-Myb) is a
member of the helix-turn-helix transcriptional activator
family. c-Myb regulates diﬀerentiation and proliferation in
immature hematopoietic and lymphoid cells, although the
relationship of the c-Myb family to the interferon system
remains undeﬁned[39].CBPbindsviaitsKIXdomaintothe
activation domain of c-Myb and mediates c-Myb-dependent
transcriptional activation [40]. c-Myb interacts with CBP,
and the acetylation of c-Myb enhances both its aﬃnity for
CBP and its capacity for transactivation.
The current list of acetylated proteins includes, amongst
o t h e r s ,p 5 3 ,M y b ,G A T A - 1 ,S p 1 ,a n dM y o D[ 2, 41, 42].
In most cases, this modiﬁcation potentiates transcription.
Acetylation causes enhanced sequence-speciﬁc DNAbinding
for transcription factors like p53, E2F, EFLF, p50, and
PC4 whereas it reduces DNA binding for other factors like
Foxo1, HMG1(Y), and p65. The impact upon DNA binding
dependson the sites ofacetylation. p53 is a sequence-speciﬁc
transcription factor that is acetylated by p300/CBP [43],
and acetylation at lysine residues in the C-terminus of p53
activates its DNA binding. Its function directly depends
upon its ability to bind to the promoters of its regulatory
genes in a sequence-speciﬁc fashion and thus maintain
cellular homeostasis. NF-kB is involved in IFN signaling.
The NF-kB/REL family of transcription factors pivotally
controls the inﬂammatory and immune responses, as well
as other genetic programs that are central to cell growth
and survival. NF-kB acetylated by p300/CBP inhibits its
interaction with IkB and induces translocation of the factor
to the nucleus. Acetylationof NF-kBis regulated by the prior
phosphorylation. HDAC3 deacetylates NF-kB,and enables it
to bind IKB and causes its translocation into the cytoplasm.
Thus, acetylation, like phosphorylation, is important for
regulating the nuclear functions of NF-kB [44].
9. FutureDirection
There are many reports about the hematopoietic and
immune regulation of IRFs, which have been demonstrated
using primary cellsfrommice [45–48].However,itisunclear
how acetylation or HAT association with IRFs function
aﬀect the immune and hematopoietic systems in vivo. In
an IFN-regulating or cell growth control system in vitro,
HATs are important factors for the correct functioning of
IRFs as well as NF-KB and p53. IRFs/HATs complex may
associate orcorrelatewith otherfactors includingNF-kBand
p53. Recently, other posttranscriptional modiﬁcation such
as methylation, ubiquitination, and sumoylation have also
been investigated for many transcription factors. Some of
these modiﬁcations’ targets are also lysine residues. A recent
report showed that sumoylation of IRF-1 or IRF-2 regulates
theirtranscriptional activities [49, 50].We should investigate
how these modiﬁcations might crosstalk with each other to
regulate the transcription factor-mediated homeostasis. Fur-
ther studies are necessary for clarifying the interaction with
acetylation and other modiﬁcations of transcription factors.
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